Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.» Read More
My recent posts on Genentech trying to crack down on doctors using its cheaper cancer drug Avastin instead of the more expensive Lucentis to treat patients with age-related macular degeneration--elicited a lot of emails from readers all over the world.
Just months after launching what was hailed as a revolutionary new product, Pfizer is taking it off the market. And it has nothing to do with safety. It has everything to do with sales--or the lack, thereof. The world's biggest drug company only recently started direct-to-consumer advertising for Exubera, but it apparently didn't work.
Insurer UnitedHealth Group posted a better-than-expected 15 percent rise in quarterly profit Thursday, helped by its Medicaid and seniors businesses.
Europe's major stock indexes closed higher Wednesday, following a mixed morning, as a strong set of earnings from the likes of Coca-Cola and JPMorgan boosted investor confidence.
German reinsurance company Munich Re will acquire specialty insurance company Midland for $1.3 billion, or $65 per share in a bid to expand in the US, the companies said on Wednesday.
“Power Lunch” is in Seattle to focus on the things that put the Pacific Northwest on the map, including the Internet and socially-conscious energy. Here's what some of the guests on the program are saying.
British life insurer Resolution on Wednesday rejected a takeover approach from rival Pearl that valued it at around 4.5 billion pounds ($9.2 billion).
Ambac Financial Group, one of the world's largest bond insurers, warned on Wednesday that it expects to report a third-quarter net loss after taking a $743 million write-down on its credit derivative portfolio.
German insurer Allianz is sticking to its full-year earnings forecast despite the impact of a credit crisis that will weigh on the trading result at its Dresdner Bank unit in the third qarter, its finance chief told Boerse Online magazine.
Discussing leadership, motivation and career success with Jack Welch, former General Electric chairman & CEO.
Pfizer put out a press release this morning announcing that it has added another office in the C-Suite. The world's biggest drug company has hired a CTO. What's a CTO, you ask?? Well, it doesn't stand for what you might guess--Chief Technology Officer. Nope, Pfizer has created the position of Chief Talent Officer.
The head of Marsh & Mclennan either needs to pack up shop or split his company up if he wants out of Cramer's Hall of Shame.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Shares in British reinsurance broker Benfield jumped almost 13% on Friday after a report it had received a 700 million pound ($1.4 billion) bid approach from the private equity arm of Goldman Sachs.
Insurer Pearl is preparing to make an all-cash offer for rival Resolution as early as next week, the Financial Times reported on Thursday.
The Lloyd's of London insurance market's pretax profit for the first six months of the year jumped 34% thanks to high premiums and low catastrophe claims, it said on Thursday.
U.K. insurer Standard Life is considering a cash-and-shares bid for Resolution, it said on Wednesday, once again throwing into doubt Resolution's agreed nil-premium merger with rival Friends Provident.
Marsh & McLennan said Friday that Brian Storms, CEO of the insurance broker's main operating subsidiary Marsh Inc., had been ousted. His departure, effective immediately, follows a 21 percent decline in Marsh & McLennan's stock price since May because of its financial underperformance.
Recently I blogged about the hiring of a new CEO at ImClone Systems and the unique clause in his contract requiring him to buy half-a-million dollars worth of stock in the company. My suspicion was that ImClone Chairman and billionaire shareholder Carl Icahn had a hand in that.
So, I thought I'd be spending today monitoring the webcast of the FDA Advisory Committees that are meeting to decide whether doctors should use less of the anemia drugs from Amgen and Johnson & Johnson to treat kidney dialysis patients.
Swiss Re said it estimated claims for the industry from natural catastrophes in 2007 would amount to about $35 billion, well above a benign 2006 with $12 billion in natural catastrophe claims.
Get the best of CNBC in your inbox